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Abstract
Compulsive-Impulsive Sexual Behaviors (C-ISBs) include repetitive sexual acts and compulsive
sexual thoughts which occur so frequently and with such intensity that they interfere with sexual
intimacy and interpersonal and occupational functioning and whose categorization and effective
treatments are still unclear. We report the case of a patient affected by C-ISBs and bipolar disorder
of type II who improved dramatically after three months' addition of topiramate to citalopram.
Topiramate is a powerful anticonvulsant which has recently been proposed also for the treatment
of migraine, bipolar disorder and binge eating disorder. This case-report suggests that topiramate
might be beneficial in augmentation with citalopram in patients suffering from C-ISBs, although
controlled studies to confirm our findings are needed.
Intrroduction
Compulsive-Impulsive Sexual Behaviors (C-ISBs) include
repetitive sexual acts and compulsive sexual thoughts. The
individual feels compelled or driven to perform the
behavior, which may or may not cause subjective distress.
Although generally not ego-dystonic, the behavior may
interfere with several aspects of the patient's life, causing
social or occupational impairment, or legal and financial
consequences [1,2]. C-ISBs involve a broad range of para-
philic or nonparaphilic symptoms [3]. Paraphilic C-ISBs
involve unconventional sexual behaviors in which there is
a disturbance in the object of sexual gratification or in the
expression of sexual gratification (e.g., exhibitionism,
voyeurism). Nonparaphilic C-ISBs, on the other hand,
involve conventional sexual behaviors that have become
excessive or uncontrolled [3]. The true prevalence of C-
ISBs remains unknown, given the hetereogeneity of these
disorders as well as the secretiveness of the condition for
the majority of the afflicted patients. Investigations con-
ducted in the early 1990s reported prevalence estimates of
I-CSBs ranging from 5% to 6% of the US population [3,4]
Although C-ISBs seem relatively common, controlled tri-
als on pharmacological treatments for these disorders are
still lacking, and the available literature on this topic con-
sists essentially of open-label and case-report series. Posi-
tive findings have been reported with lithium and
tricyclics [5-7], selective serotonin reuptake inhibitors [8-
11], buspirone [12,13] and nefazodone [14]. In addition,
the opioid antagonist naltrexone has recently been shown
to be efficacious in some case-reports [15]. Finally, differ-
ent forms of psychotherapy have been shown to be effec-
tive for specific subtypes of C-I sexual behaviors [16].
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Clinical Practice and Epidemiology in Mental Health 2006, 2:9 http://www.cpementalhealth.com/content/2/1/9Topiramate is an orally active anticonvulsant whose
mechanisms of action include potentiation of GABA to
activate GABAA receptors and antagonism of glutamate at
specific receptors [17,18]. Although the efficacy of topira-
mate has not been evaluated yet in the treatment of C-
ISBs, previous reports suggest that this compound might
be beneficial in a variety of psychiatric illnesses including
affective disorders [19,20], eating disorders [21], post-
traumatic stress disorder [22] and obsessive-compulsive
disorder (OCD) [23]. In addition, some authors [24] have
reported an overlap between C-ISBs and OCD and
included C-ISBs in a broader obsessive-compulsive spec-
trum including also impulse-control disorders such as
pathological gambling (PG), eating disorders such as
binge eating disorder (BED), and other mental conditions
such as body dysmorphic disorder and autism. Finally
topiramate' putative mood stabilizer properties [19,20]
may represent an additional advantage for its use in sub-
jects with comorbid bipolar disorder, like the patient we
report here who was successfully treated with a pharmaco-
logical augmentation of topiramate plus citalopram.
Case report
Mr. A, male, 32 years old, had been suffering since his late
teens from C-ISBs in the form of episodes (5–7 a year last-
ing from 7 to 10 days) of hypersexuality characterized by
repetitive masturbation and sexual intercourse (up to 25–
30 times a day). On reaching his twenties, having finished
school and with a job and salary, he started to meet pros-
titutes. Episodes became more frequent and his need of
compulsive sexual intercourse (up to 30 times in one day)
was so intense that he could waste all his salary in just a
few days. He developed a depressive episode requiring
hospitalization in a day-hospital. The patient was diag-
nosed as suffering from C-ISBs and bipolar disorder of
type II and was initially treated with sertraline (100 mg/d)
and lithium salts (900 mg/d). After two months, the
depressive symptoms had disappeared, but the patient
refused to continue with the mood stabilizer because of
significant weight gain (8 kilos). During the subsequent
years he presented episodes of opposed polarity, with the
presence throughout of C-ISBs, egodystonic when
depressed and egosyntonic when euphoric, but he could
not take any of the prescribed mood stabilizers, including
valproate, carbamazepine, oxcarbamazepine, lamotrig-
ine, or gabapentin, because of various side effects.
His most recent severe depressive episode occurred in the
autumn of 2002: he had been depressed after spending
his entire salary in just one day with prostitutes, and, on
that occasion, had expressed suicidal intention. He was
treated with benzodiazepines (only in the first week) and
citalopram 20 mg/d, titrated up to 60 mg/d in two weeks.
Then adjunctive topiramate was added to his current treat-
ment at an initial dosage of 50 mg, which was titrated up
to 200 mg/d in one month. After three months of this
pharmacological regimen, depressive symptoms and sex-
ual urges were significantly decreased and citalopram was
reduced progressively until cessation. The patient was
maintained on topiramate only which, given the mild
mood shifts, was increased to 400 mg/d and continued for
one year, with no relevant side-effects. During this period
the patient experienced for the first time in his life a long
period of stability with a normal arousal pattern, and he
began a loving relationship which is still ongoing.
Discussion
C-ISBs are characterized by abnormal sexual behaviour in
terms of frequency and intensity of arousal patterns,
which provokes significant subjective sufferance, as well
as impairment of social relationship and work activities.
In addition, the stigma related to sexual (and mental) dis-
turbances understandably represents an obstacle to relia-
ble information on the prevalence of C-ISBs and this also
provides an explanation of the few clinical studies in the
field.
Although prevalent and impairing, C-ISBs have not been
systematically investigated form a pharmacological point
of view, and different medications have demonstrated to
be effective, although generally not in randomised con-
trolled trials [25]. The efficacy of many pharmacological
treatments in C-ISBs could also reflect the various dimen-
sional approaches to C-ISBs in terms of psychopathologic
and clinical similarities and overlaps with other Axis I dis-
orders. In fact, the most consistent findings on this topic
tend to categorize C-ISBs either as an impulse control dis-
order or as an entity belonging to the bipolar spectrum
disorders: this represents the rationale for the use of mood
stabilizers in C-ISBs.
The case report described herein underlines this link
between C-ISBs and bipolar spectrum disorders and sug-
gests that, amongst mood stabilizers, topiramate might be
particularly useful in the broader area of impulse control
disorders. However, topiramate-induced cases of
hypomanic and manic episodes have also been reported
in literature [26,27]. Nevertheless, the pharmacological
profile of topiramate including a rapid onset of action
along with a low weight gain liability and sexual dysfunc-
tion may represent a further interesting feature for future
research with this drug.
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